A gene called DOT1L appears to play a role in progression and severity of ovarian cancer, and inhibitors of the DOT1L enzyme may offer a new therapeutic approach for the disease, University of Alabama at Birmingham researchers say in a … Read more
By Ariana Pelosci
Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.
The identification of social needs and accompanying solutions could result in more actionable health care disparities … Read more
DALLAS – July 30, 2021 – UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.… Read more
For a second time, researchers will test an antibiotic discovered in the 1950s as a potential treatment for cancer.
The first attempt to study the drug, novobiocin, in patients with cancer was a small clinical trial conducted 30 years ago. … Read more
Researchers at Texas A&M University are pushing organ-on-a-chip devices to new levels that could change the way clinicians approach cancer treatment, particularly ovarian cancer. A team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station.… Read more
A new study published online today in the Journal of the National Cancer Institute reports that one third of the most popular cancer treatment articles on social media contain misinformation. Further, the vast majority of that misinformation has the potential … Read more
CAMBRIDGE, England — Virtual biopsies could replace invasive tissue procedures and give more accurate results thanks to a revolutionary new method developed using computer scans. The new advanced computing technique uses routine medical scans to enable doctors to take fewer, … Read more
By Alan Mozes
Could a new one-and-done blood test designed to detect as many as 50 different types of cancer become a diagnostic game changer?
Yes, say researchers, who report the method appears accurate and reliable at identifying and locating … Read more
Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA.… Read more
By Mike Bassett
Dampened responses seen in those with hematological malignancies, however patients with cancer who were vaccinated against COVID-19 achieved high seroconversion rates, a single-center study found.
The rate of seroconversion was especially high among patients with solid tumors … Read more
Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1… Read more
An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 … Read more
In a prospective study in Israel, 90% of cancer patients were seropositive for antibodies
By Mike Bassett
The vast majority of patients undergoing active systemic therapy for cancer exhibited an adequate immune response to the Pfizer/BioNTech COVID-19 vaccine, according to … Read more
By Professor Ian Jacobs
I was motivated to improve the outcome for women with ovarian cancer by my experience as a junior doctor in London in 1985. But 36 years on, the results aren’t what we’d hoped.
My colleages’ and
… Read moreBy Pam Harrison
Results from a huge British trial that involved more than 200,000 women who were followed for a median of 16 years have turned out negative. Investigators found that annual screening for ovarian cancer with either multimodal screening … Read more
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
The research from UVA’s Jogender Tushir-Singh, PhD, explains why … Read more
Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study.
By Charles Bankhead
Two drugs outperformed one for hyperthermic intraperitoneal chemotherapy (HIPEC) after interval surgical debulking of advanced ovarian cancer, data from a prospective registry showed.
Median progression-free survival (PFS) doubled … Read more
High tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology.
The findings suggest that … Read more
